These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30632692)

  • 1. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.
    Siwy J; Klein T; Rosler M; von Eynatten M
    Proteomics Clin Appl; 2019 Mar; 13(2):e1800144. PubMed ID: 30632692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
    Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
    Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.
    Klein T; Tammen H; Mark M; Benetti E; Delić D; Schepers C; von Eynatten M
    Diabetes Obes Metab; 2021 Aug; 23(8):1968-1972. PubMed ID: 33881796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
    Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K
    Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
    Hasan AA; von Websky K; Reichetzeder C; Tsuprykov O; Gaballa MMS; Guo J; Zeng S; Delić D; Tammen H; Klein T; Kleuser B; Hocher B
    Kidney Int; 2019 Jun; 95(6):1373-1388. PubMed ID: 30979564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
    Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
    Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.
    Luippold G; Mark M; Klein T; Amann K; Daniel C
    Diabetes Res Clin Pract; 2018 Sep; 143():199-203. PubMed ID: 30031047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.
    Lietzau G; Davidsson W; Östenson CG; Chiazza F; Nathanson D; Pintana H; Skogsberg J; Klein T; Nyström T; Darsalia V; Patrone C
    Acta Neuropathol Commun; 2018 Feb; 6(1):14. PubMed ID: 29471869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MARLINA-T2D trial: putting the results into clinical perspective.
    Lajara R
    Expert Rev Endocrinol Metab; 2018 May; 13(3):173-176. PubMed ID: 30058901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
    Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
    Lietzau G; Magni G; Kehr J; Yoshitake T; Candeias E; Duarte AI; Pettersson H; Skogsberg J; Abbracchio MP; Klein T; Nyström T; Ceruti S; Darsalia V; Patrone C
    Neurobiol Aging; 2020 May; 89():12-23. PubMed ID: 32143981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
    Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
    Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats.
    Helmy MM; Mouneir SM
    Pharmacol Rep; 2019 Dec; 71(6):1133-1139. PubMed ID: 31675669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.
    Fadini GP; Bonora BM; Cappellari R; Menegazzo L; Vedovato M; Iori E; Marescotti MC; Albiero M; Avogaro A
    J Clin Endocrinol Metab; 2016 Feb; 101(2):748-56. PubMed ID: 26695864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
    Spencer NY; Yang Z; Sullivan JC; Klein T; Stanton RC
    PLoS One; 2018; 13(7):e0200249. PubMed ID: 29979777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
    Tamborlane WV; Laffel LM; Weill J; Gordat M; Neubacher D; Retlich S; Hettema W; Hoesl CE; Kaspers S; Marquard J
    Pediatr Diabetes; 2018 Jun; 19(4):640-648. PubMed ID: 29171139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.